ATC Group: L01XX67 Tagraxofusp

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01XX67 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01X Other antineoplastic agents
4 L01XX Other antineoplastic agents
5 L01XX67

Active ingredients in L01XX67

Active Ingredient

Tagraxofusp is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123-expressing cells. It is used for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Related product monographs

Document Type Information Source  
 ELZONRIS Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)

Medicines in this ATC group

United States (US)

Croatia (HR)

Estonia (EE)

Ireland (IE)

Lithuania (LT)

Poland (PL)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.